Castle Biosciences stock kpis
Want to see CSTL full AI Analyst Report?
Net Revenue by Segment
Castle Biosciences reported net revenue by segment of $102.89M in Q3 2026, down 0.6% from Q2 2026 and up 23.9% year over year. The highest value was $103.55M in Q2 2026.
Shows how much money each part of the business brings in — for Castle Biosciences that typically means different diagnostic tests, services, and regions. Reveals whether growth is coming from a single flagship test or from broader product adoption, highlights concentration risk if one segment dominates, and points to where reimbursement, pricing, or commercial efforts are succeeding or need more investment.
Revenue mix is shifting: Non‑dermatologic businesses have moved from a niche contributor into a co‑equal (now leading) growth engine, powered by rapid TissueCypher expansion and other non‑derm tests, while the once‑dominant dermatologic cohort rolled over after mid‑2024 peaks—partly seasonal and partly pressured by DecisionDx‑SCC reimbursement timing and capacity/cost investments. Management’s raised guidance and volume momentum support further top‑line upside, but sustainable margin improvement hinges on mix normalization, reimbursement clarity, and successful commercialization of Advanced ADTx.
CSTL Net Revenue by Segment
| Period | Dermatologic | Non-Dermatologic | Total |
|---|---|---|---|
| Q3 2026Sep 30, 2026 | $47.88M | $55.01M | $102.89M |
| Q2 2026Jun 30, 2026 | $48.70M | $54.84M | $103.55M |
| Q1 2026Mar 31, 2026 | $41.10M | $42.57M | $83.68M |
| Q4 2025Dec 31, 2025 | $48.59M | $38.42M | $87.01M |
| Q3 2025Sep 30, 2025 | $48.52M | $34.52M | $83.04M |
| Q2 2025Jun 30, 2025 | $56.30M | $29.89M | $86.19M |
| Q1 2025Mar 31, 2025 | $62.96M | $25.03M | $87.99M |
| Q4 2024Dec 31, 2024 | $63.77M | $22.54M | $86.31M |
| Q3 2024Sep 30, 2024 | $65.06M | $20.72M | $85.78M |
| Q2 2024Jun 30, 2024 | $68.83M | $18.17M | $87.00M |
| Q1 2024Mar 31, 2024 | $59.33M | $13.64M | $72.97M |
| Q4 2023Dec 31, 2023 | $53.28M | $12.84M | $66.12M |
| Q3 2023Sep 30, 2023 | $51.15M | $10.34M | $61.49M |
| Q2 2023Jun 30, 2023 | $43.03M | $7.11M | $50.14M |
| Q1 2023Mar 31, 2023 | $35.91M | $6.13M | $42.04M |
| Q4 2022Dec 31, 2022 | $34.65M | $3.69M | $38.34M |
| Q3 2022Sep 30, 2022 | $33.92M | $3.09M | $37.01M |
| Q2 2022Jun 30, 2022 | $31.90M | $2.94M | $34.84M |
| Q1 2022Mar 31, 2022 | $24.34M | $2.51M | $26.85M |
| Q4 2021Dec 31, 2021 | $22.87M | $2.17M | $25.04M |
| Q3 2021Sep 30, 2021 | $21.59M | $1.88M | $23.48M |
| Q2 2021Jun 30, 2021 | $20.38M | $2.38M | $22.76M |
| Q1 2021Mar 31, 2021 | $20.91M | $1.90M | $22.81M |

